Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
28 hedge funds and large institutions have $1.68M invested in Nymox Pharmaceutical Corp in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 14 reducing their positions, and 6 closing their positions.
1% more call options, than puts
Call options by funds: $149K | Put options by funds: $148K
10% less funds holding
Funds holding: 31 → 28 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
58% less capital invested
Capital invested by funds: $3.98M → $1.68M (-$2.3M)
86% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
+$130K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$26.5K |
| 3 |
WB
Webster Bank
Waterbury,
Connecticut
|
+$23.6K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$182 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$730K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$249K |
| 3 |
WP
WMS Partners
Towson,
Maryland
|
-$104K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$88K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$80.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Geode Capital Management
Boston,
Massachusetts
| $34 | -$184 | -78 | -0.5% |
|
|
OAM
27
Oxford Asset Management
Oxford,
United Kingdom
| – | -$88K | -26,256 | Closed |
|
|
ARTA
28
A.R.T. Advisors
New York
| – | -$77K | -23,511 | Closed |
|
|
VKH
29
Virtu KCG Holdings
New York
| – | -$54K | -16,572 | Closed |
|
30
Walleye Trading
New York
| – | -$29K | -8,800 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$10.7K | -4,541 | -98% |
|
|
IA
32
IFP Advisors
Tampa,
Florida
| – | -$2K | -540 | Closed |
|
|
33
UBS Group
Zurich,
Switzerland
| – | +$182 | +77 | New |
|
NYMX Hedge Fund Activity: Q1 2016 in Review
28 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2016, worth a combined $1.68M — down 58% from $3.98M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NYMX and 3 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 2 added.
The largest buyer was Marathon Capital Management, opening a new position worth an estimated $130K. The largest seller was Morgan Stanley, cutting an estimated $730K.
- 28 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2016, down from 31 in Q4 2015.
- Funds reported $1.68M of Nymox Pharmaceutical Corp stock for Q1 2016, down 58% quarter-over-quarter.
- 3 funds opened new Nymox Pharmaceutical Corp positions in Q1 2016 and 6 closed out, a net change of -3 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q1 2016 was Marathon Capital Management, an estimated $130K added.
- The largest Nymox Pharmaceutical Corp seller in Q1 2016 was Morgan Stanley, an estimated $730K sold.
Based on aggregated 13F filings for Q1 2016.